CT site successfully recruited minorities for HIV vaccine study

June 2009
Clinical Trials Administrator;Jun2009, Vol. 7 Issue 6, p69
The article deals with the enrollment of minorities for an HIV vaccine clinical trial (CT) in the U.S. It states that enrolling minorities in several HIV clinical trials is prioritized, particularly African Americans, because African Americans are disproportionately affected by the HIV/AIDS epidemic in the country. One of the strategies used by the CT staff for the study was to provide face-to-face activities in order to recruit African American women.


Related Articles

  • Phase I Trials of Preventive HIV/AIDS Vaccines Worldwide (August 2007).  // AIDS Alert;Oct2007, Vol. 22 Issue 10, p4 

    A list of Phase I trials of preventive HIV/AIDS vaccines worldwide, as of August 2007.

  • Researchers halt HIV vaccine trial -- What's the next step? Bower, Rebecca // AIDS Alert;Jan2008, Vol. 23 Issue 1, p8 

    The article reports on the cessation of an HIV vaccine clinical trial conducted by Merck & Co.

  • Some statistical issues in the design of HIV-1 vaccine and treatment trials. Gilbert, P.B. // Statistical Methods in Medical Research;Jun2000, Vol. 9 Issue 3, p207 

    This article summarizes material on statistical issues in the design of HIV-1 preventive vaccine trials and antiretroviral HIV-1 treatment trials that was presented at the first school on Modern Statistical Methods in Medical Research, held at the International Centre for Theoretical Physics in...

  • Merck HIV Vaccine Ineffective in Clinical Trial.  // Internal Medicine Alert;11/15/2007, Vol. 29 Issue 21, p2 

    The article reports on the announcement from Merck pharmaceutical company that their HIV vaccine is ineffective in a large clinical trial and that the company has terminated further test vaccinations.

  • Early Results of Therapeutic AIDS Vaccine Show Benefit. Kingman, Sharon // BioWorld International;11/17/2010, Vol. 15 Issue 45, p1 

    This article reports on the success of a Phase II trial of a therapeutic HIV vaccine conducted in Rome, Italy. The study involved giving a vaccine made from recombinant biologically active Tat protein. It has been expanded to recruit more participants. The implications of the study are discussed...

  • VACCINE TRIALS BEGIN. Harding, Rick // Advocate;9/29/87, Issue 482, p10 

    Focuses on the clinical trials of an AIDS vaccine in the U.S. Participation of gays in the clinical trials of the vaccine; Risks for trial volunteers; Phases of the trial.

  • VACCINE TRIALS BEGIN: A HOPE AND A WARNING.  // Advocate;9/29/87, Issue 482, p19 

    Focuses on the clinical trials of an experimental AIDS vaccine in the U.S. Use of genetic engineering technology in vaccine development; Role of the gay community to prevent the spread of AIDS.

  • On the trail of two trials. Moore, John P. // Nature;1/24/2002, Vol. 415 Issue 6870, p365 

    Investigates the impact of duplicative clinical trials on the development of an AIDS vaccine in the U.S. Estimated number of people infected by HIV-1 as of January 2002; Involvement of government in vaccine-trial programs; Evaluation of recombinant canarypox immunogen in humans.

  • Experimental AIDS vaccine being tested on humans.  // Gay & Lesbian Times;1/30/2003, Issue 788, p26 

    Reports on the human testing of an AIDS vaccine developed at Emory University in Atlanta, Georgia. Volunteers enrolled in the initial series of clinical trials at the San Francisco Department of Public Health in California, University of Alabama-Birmingham and the University of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics